The company's capital structure has shifted toward significant leverage, with total debt rising to $63.6 million and a debt-to-equity ratio of 3.37 as of 2026Q1.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 |
|---|
| Total Current Assets | 54.88M | 63.6M | 33.36M | 36.17M | 51.18M | 61.89M | 25.46M | 10.38M | 6.65M | 12.75M | 6.09M | 8.53M | 11.71M | 5.94M | 3.08M | 1.54M |
| Cash & Short-Term Investments | 35.59M | 45.92M | 20.1M | 23.14M | 37.49M | 54.11M | 20.1M | 5.7M | 3.1M | 9.29M | 3.32M | 5.41M | 9.24M | 3.52M | 1.62M | 145.48K |
| Cash Only | 35.59M | 45.92M | 20.1M | 23.14M | 27.61M | 54.11M | 20.1M | 5.7M | 3.1M | 9.29M | 3.32M | 5.41M | 9.24M | 3.52M | 1.62M | 145.48K |
| Short-Term Investments | 0 | 0 | 0 | 0 | 9.87M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 8.66M | 7.26M | 4.71M | 3.94M | 2.67M | 2.34M | 1.88M | 1.09M | 1.23M | 949.41K | 865.94K | 1.22M | 468.95K | 770.35K | 445.43K | 401.58K |
| Days Sales Outstanding | 54.34 | 71.7 | 54.8 | 60.09 | 47.33 | 52.33 | 53.52 | 35.47 | 61.25 | 46.96 | 54.97 | 96.77 | 47.49 | 71.54 | 32.14 | 38.39 |
| Inventory | 8.57M | 8.36M | 6.86M | 7.91M | 9.3M | 4.94M | 3.24M | 3.24M | 2.11M | 2.31M | 1.77M | 1.81M | 1.97M | 1.48M | 899.7K | 968.82K |
| Days Inventory Outstanding | 175.43 | 213.67 | 204.19 | 279.23 | 483.7 | 348.22 | 318.65 | 300 | 315.93 | 291.39 | 244.24 | 331.99 | 372.18 | 379.39 | 590.95 | 538.71 |
| Other Current Assets | 2.05M | 2.06M | 1.68M | 0 | 1.72M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 38.54M | 34.15M | 5.83M | 6.49M | 4.31M | 3.69M | 4.06M | 1.54M | 1.2M | 1.15M | 1.32M | 1.57M | 1.68M | 1.93M | 2.48M | 1.49M |
| Property, Plant & Equipment | 16M | 11.05M | 5.09M | 4.95M | 2.7M | 2.78M | 3.06M | 821K | 377.71K | 267.67K | 328.25K | 440.61K | 482.97K | 903.16K | 1.29M | 1.22M |
| Fixed Asset Turnover | 3.75x | 3.35x | 6.17x | 4.84x | 7.61x | 5.86x | 4.20x | 13.66x | 19.47x | 27.57x | 17.52x | 10.43x | 7.46x | 4.35x | 3.93x | 3.13x |
| Goodwill | 7.47M | 7.47M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 13.42M | 13.92M | 484K | 1.04M | 1.03M | 265K | 353K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.14M | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.65M | 1.7M | 251K | 495K | 581K | 644K | 648K | 722K | 824.44K | 883.54K | 987.54K | 1.13M | 1.2M | 1.03M | 51.12K | 275.95K |
| Total Assets | 93.42M | 97.75M | 39.19M | 42.66M | 55.49M | 65.58M | 29.52M | 11.93M | 7.86M | 13.9M | 7.4M | 10.1M | 13.39M | 7.87M | 5.55M | 3.03M |
| Asset Turnover | 0.52x | 0.38x | 0.80x | 0.56x | 0.37x | 0.25x | 0.43x | 0.94x | 0.94x | 0.53x | 0.78x | 0.45x | 0.27x | 0.50x | 0.91x | 1.26x |
| Asset Growth % | 429.84% | 149.42% | -8.14% | -23.12% | -15.39% | 122.17% | 147.49% | 51.8% | -43.47% | 87.78% | -26.74% | -24.53% | 70.02% | 41.81% | 83.2% | - |
| Total Current Liabilities | 9.48M | 10.77M | 10.35M | 7.43M | 6.79M | 4.75M | 3.2M | 3.83M | 2.01M | 4.4M | 3.02M | 7.65M | 4.92M | 10.09M | 4.18M | 14.59M |
| Accounts Payable | 2.33M | 1.26M | 1.34M | 393K | 272K | 427K | 300K | 966K | 500.93K | 759.45K | 1.55M | 697.81K | 997.09K | 1.38M | 1.96M | 4.04M |
| Days Payables Outstanding | 34.37 | 32.11 | 39.87 | 13.87 | 14.14 | 30.11 | 29.52 | 89.44 | 75.15 | 95.62 | 213.65 | 128.14 | 188.85 | 353.57 | 1.29K | 2.24K |
| Short-Term Debt | 234K | 694K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2M | 0 | 4.22M | 0 | 4.34M | 0 | 3.95M |
| Deferred Revenue (Current) | 3.1M | 0 | 2.12M | 2.61M | 1.07M | 678K | 562K | 1.02M | 350.96K | 256.18K | 223.12K | 116.01K | 102.71K | 106.86K | 762.73K | 2.6M |
| Other Current Liabilities | 6.92M | 8.81M | 4.88M | 2.95M | 2.82M | 2.6M | 1.59M | 1.41M | 741.8K | 575.95K | 581.6K | 2.06M | 3.5M | 4.06M | 1.18M | 1.01M |
| Current Ratio | 5.79x | 5.91x | 3.22x | 4.87x | 7.54x | 13.02x | 7.96x | 2.71x | 3.31x | 2.90x | 2.02x | 1.11x | 2.38x | 0.59x | 0.74x | 0.11x |
| Quick Ratio | 4.88x | 5.13x | 2.56x | 3.80x | 6.17x | 11.98x | 6.95x | 1.86x | 2.27x | 2.37x | 1.43x | 0.88x | 1.98x | 0.44x | 0.52x | 0.04x |
| Cash Conversion Cycle | 195.39 | 253.27 | 219.12 | 325.45 | 516.89 | 370.44 | 342.64 | 246.02 | 302.03 | 242.72 | 85.56 | 300.62 | 230.82 | 97.36 | -665.07 | -1.67K |
| Total Non-Current Liabilities | 65.09M | 58.96M | 3.45M | 14.06M | 11.81M | 12.04M | 23.94M | 3.51M | 4.34M | 3.67M | 5.14M | 4.43M | 8.57M | 4.62M | 7.11M | 10.28M |
| Long-Term Debt | 49.64M | 49.08M | 0 | 9.95M | 9.89M | 9.84M | 21.28M | 2.07M | 3.48M | 2.92M | 4.49M | 3.72M | 7.69M | 4.08M | 6.53M | 3.5M |
| Capital Lease Obligations | 34.65M | 8.46M | 3.01M | 3.57M | 1.53M | 1.94M | 2.45M | 277K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 708K | 354K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 779K | 489K | 0 | 0 | 0 | 0 | 0 | 960K | 997.7K | 752.5K | 647.5K | 542.5K | 876.02K | 531.83K | 574.72K | 5.39M |
| Total Liabilities | 74.58M | 69.73M | 13.8M | 21.49M | 18.6M | 16.79M | 27.14M | 7.34M | 6.35M | 8.07M | 8.16M | 12.08M | 13.49M | 14.71M | 11.29M | 24.87M |
| Total Debt | 63.59M | 58.23M | 3.57M | 13.94M | 11.99M | 12.28M | 24.12M | 2.46M | 3.48M | 4.92M | 4.49M | 8.11M | 7.69M | 8.42M | 6.53M | 7.46M |
| Net Debt | 28M | 12.31M | -16.54M | -9.2M | -15.63M | -41.83M | 4.02M | -3.23M | 379.51K | -4.37M | 1.18M | 2.7M | -1.55M | 4.91M | 4.91M | 7.31M |
| Debt / Equity | 3.37x | 2.08x | 0.14x | 0.66x | 0.32x | 0.25x | 10.15x | 0.54x | 2.30x | 0.84x | - | - | - | - | - | - |
| Debt / EBITDA | -2.67x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -1.18x | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -9.82x | -10.12x | - | - | -201.90x | -13.81x | -3.70x | -4.80x | -5.29x | -7.21x | -6.62x | -5.69x | -3.44x | -13.18x | -1.27x | -2.33x |
| Total Equity | 18.84M | 28.02M | 25.39M | 21.17M | 36.89M | 48.79M | 2.38M | 4.59M | 1.51M | 5.83M | -756.07K | -1.98M | -100.33K | -6.83M | -5.74M | -21.84M |
| Equity Growth % | -79.19% | 10.36% | 19.91% | -42.6% | -24.39% | 1952.46% | -48.17% | 203.51% | -74.08% | 870.93% | 61.84% | -1874.62% | 98.53% | -19.12% | 73.73% | - |
| Book Value per Share | 0.64 | 0.99 | 0.94 | 0.86 | 1.53 | 2.35 | 0.15 | 0.35 | 0.14 | 0.75 | -0.27 | -1.05 | -0.07 | -4.77 | -5.68 | -54.47 |
| Total Shareholders' Equity | 18.84M | 28.02M | 25.39M | 21.17M | 36.89M | 48.79M | 2.38M | 4.59M | 1.51M | 5.83M | -756.07K | -1.98M | -100.33K | -6.83M | -5.74M | -21.84M |
| Common Stock | 300K | 294K | 276K | 247K | 246K | 237K | 170K | 152K | 110.18K | 106.94K | 36.22K | 913.81K | 748.42K | 585.37K | 484.19K | 164.11K |
| Retained Earnings | -226.46M | -216.91M | -191.37M | -172.46M | -150.37M | -133.93M | -119.52M | -112.74M | -107.2M | -101.04M | -93.87M | -85.73M | -77.28M | -72.75M | -65.5B | -59.79M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1.68M | -1.68M |
| Accumulated OCI | 5.54M | 5.64M | 0 | 0 | 0 | 0 | 0 | 0 | -1.72M | -1.67M | -1.71M | -1.73M | -1.74M | -72.75M | -65.5M | -59.79M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
High debt-to-equity leverage
Based on reported financial statements, CLPT's balance sheet has shifted from a net-cash position in 2024Q1 to a debt-heavy structure by 2026Q1, with total liabilities rising to $74.6 million, signaling that the company's growth trajectory is increasingly reliant on external financing rather than internal capital generation.
The rapid expansion of total liabilities relative to equity suggests that the company is aggressively leveraging its balance sheet to fund its strategic pivot. Investors should monitor whether this debt-fueled expansion can eventually translate into self-sustaining operational cash flows before the current capital structure becomes unsustainable.
As indicated in recent SEC filings, CLPT's total debt surged to $63.6 million in 2026Q1, driving the debt-to-equity ratio to a concerning 3.37, which suggests that the company's reliance on debt financing has significantly increased to support its ongoing operational and capital expenditure requirements.
This elevated leverage profile may limit the company's financial flexibility, particularly if the anticipated biologics-enablement revenue fails to materialize at the expected scale. The shift from a 0.13 D/E ratio in 2024Q3 to current levels warrants close scrutiny regarding the company's ability to service these obligations.
According to the 2026Q1 balance sheet, CLPT holds $35.6 million in cash, which, when viewed against the backdrop of persistent operating losses and rising debt, suggests that the company's liquidity buffer is under significant pressure despite a reported current ratio of 5.79.
While the current ratio appears healthy on the surface, the high debt load and consistent cash burn indicate that the company's actual liquidity runway may be shorter than headline metrics imply. The reliance on external capital to maintain operations remains a primary risk factor for shareholders.
Based on the provided data, CLPT's accumulated deficit has ballooned to -$226.5 million as of 2026Q1, a figure that highlights the long-term erosion of shareholder equity and underscores the fundamental challenge of achieving profitability within the company's current high-cost, specialized medical device business model.
The persistent growth in the accumulated deficit suggests that the company's historical capital allocation has yet to yield a return on invested capital that exceeds its cost of funding. This trend implies that the balance sheet is effectively being used to subsidize ongoing R&D and commercialization efforts.
Quick answers to the most common questions about buying CLPT stock.
As of 2025, ClearPoint Neuro, Inc. (CLPT) had total assets of $97.7M including $63.6M in current assets.
ClearPoint Neuro, Inc. (CLPT) carries total debt of $58.2M, offset by $45.9M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
ClearPoint Neuro, Inc. (CLPT) has total shareholders' equity (book value) of $28.0M ($0.99 book value per share). Book value represents the net worth of the company belonging to common stock holders.
ClearPoint Neuro, Inc. (CLPT) reported a current ratio of 5.91x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.